Helsinn begins elsiglutide Phase IIB trial for prevention of chemotherapy … – News-Medical.net


Helsinn begins elsiglutide Phase IIB trial for prevention of chemotherapy
News-Medical.net
Helsinn Healthcare S.A. ("Helsinn") and Zealand Pharma A/S ("Zealand") (Nasdaq Copenhagen: ZEAL) jointly announce that Helsinn has started a Phase IIB clinical dose-finding trial of elsiglutide for the prevention of chemotherapy-induced diarrhea (CID).

diarrhea – Google News